The weight loss app Noom is facing criticism after allegations surfaced that it misled users with diabetes by promoting unsubstantiated health claims. The controversy has drawn attention from the American Diabetes Association (ADA) and consumer protection groups.
What’s the controversy about?
Noom, which markets itself as a behaviour-change platform for weight management, has been accused of making misleading claims about its effectiveness for people with diabetes. Critics argue that the app’s marketing materials suggested it could help manage or even reverse diabetes without sufficient scientific backing.
Regulatory scrutiny
The ADA has raised concerns over Noom’s advertising, stating that such claims could discourage users from seeking proper medical treatment. Meanwhile, consumer advocates are calling for stricter oversight of digital health platforms to prevent misleading promotions.
Noom’s response
Noom has defended its approach, stating that its program is designed to support healthy habits and is not a substitute for medical advice. However, the company has faced previous scrutiny over its subscription model and data privacy practices.
Why this matters
With millions of Americans managing diabetes, the potential for digital health tools to mislead vulnerable users is a growing concern. Experts warn that unverified health claims could have serious consequences for those relying on accurate medical information.
